The 2016 revision of the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines provides updated recommendations for the treatment of allergic rhinitis (AR). The guidelines emphasize the use of oral H1-antihistamines, intranasal H1-antihistamines, intranasal corticosteroids, and leukotriene receptor antagonists. They also address the use of combinations of these medications and their relative effectiveness. The guidelines aim to improve patients' quality of life, school and work productivity, and asthma control by providing evidence-based recommendations for the management of AR. The ARIA guidelines were developed by a panel of experts from various countries and include recommendations for the treatment of both seasonal and perennial allergic rhinitis. The guidelines are intended for use by primary care clinicians, school nurses, pharmacists, specialists in allergy and clinical immunology, general internists, and pediatricians. They also provide guidance for other healthcare professionals and policymakers. The guidelines are based on a systematic review of the literature and the GRADE approach to evidence-based medicine. They address six specific clinical questions related to the treatment of allergic rhinitis. The recommendations are categorized as either "strong" or "conditional" based on the confidence of the panel in the effectiveness of the treatment. The guidelines emphasize the importance of considering patient values and preferences, as well as the feasibility and cost-effectiveness of treatment options. They also highlight the need for local adaptation of recommendations to ensure they are applicable in different healthcare settings. The ARIA guidelines are an important resource for healthcare professionals and patients, providing evidence-based recommendations for the management of allergic rhinitis. They aim to improve patient outcomes and reduce the burden of the disease on individuals and society. The guidelines are regularly updated to reflect new evidence and ensure that recommendations remain current and relevant.The 2016 revision of the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines provides updated recommendations for the treatment of allergic rhinitis (AR). The guidelines emphasize the use of oral H1-antihistamines, intranasal H1-antihistamines, intranasal corticosteroids, and leukotriene receptor antagonists. They also address the use of combinations of these medications and their relative effectiveness. The guidelines aim to improve patients' quality of life, school and work productivity, and asthma control by providing evidence-based recommendations for the management of AR. The ARIA guidelines were developed by a panel of experts from various countries and include recommendations for the treatment of both seasonal and perennial allergic rhinitis. The guidelines are intended for use by primary care clinicians, school nurses, pharmacists, specialists in allergy and clinical immunology, general internists, and pediatricians. They also provide guidance for other healthcare professionals and policymakers. The guidelines are based on a systematic review of the literature and the GRADE approach to evidence-based medicine. They address six specific clinical questions related to the treatment of allergic rhinitis. The recommendations are categorized as either "strong" or "conditional" based on the confidence of the panel in the effectiveness of the treatment. The guidelines emphasize the importance of considering patient values and preferences, as well as the feasibility and cost-effectiveness of treatment options. They also highlight the need for local adaptation of recommendations to ensure they are applicable in different healthcare settings. The ARIA guidelines are an important resource for healthcare professionals and patients, providing evidence-based recommendations for the management of allergic rhinitis. They aim to improve patient outcomes and reduce the burden of the disease on individuals and society. The guidelines are regularly updated to reflect new evidence and ensure that recommendations remain current and relevant.